Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Intravenous Infusions. Found 19 abstracts

Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 Nov;18(11):1483-92.
Kantarjian HM, Roboz GJ, Kropf PL, Yee KW, O'Connell CL, Tibes R, Walsh KJ, Podoltsev NA, Griffiths EA, Jabbour E, Garcia-Manero G, Rizzieri D, Stock W, Savona MR, Rosenblat TL, Berdeja JG, Ravandi F, Rock EP, Hao Y, Azab M, Issa JJ. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol. 2017 Oct;18(10):1317-26.   PMCID: PMC5925750
Schmier J, Ogden K, Nickman N, Halpern MT, Cifaldi M, Ganguli A, Bao Y, Garg V. Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center Setting. Clinical therapeutics. 2017 Aug;39(8):1600-17.
Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba, Baker LH, Maki RG, Reinke D, Patel S. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017 Nov;18(11):1493-501.
Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, DiSilvestro PA, Rubin SC, Martin LP, Davidson SA, Huh WK, O'Malley DM, Boente MP, Michael H, Monk BJ. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. The New England journal of medicine. 2016 Feb 25;374(8):738-48.   PMCID: PMC5081077
Chan JK, Java JJ, Fuh K, Monk BJ, Kapp DS, Herzog T, Bell J, Young R. The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials. Gynecol Oncol. 2016 Dec;143(3):490-5.   PMCID: PMC5728987
Peethambaram PP, Hartmann LC, Jonker DJ, de Jonge M, Plummer ER, Martin L, Konner J, Marshall J, Goss GD, Teslenko V, Clemens PL, Cohen LJ, Ahlers CM, Alland L. A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):321-31.
Mateo J, Berlin J, de Bono JS, Cohen RB, Keedy V, Mugundu G, Zhang L, Abbattista A, Davis C, Gallo Stampino C, Borghaei H. A first-in-human study of the anti-alpha5beta1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Nov;74(5):1039-46.   PMCID: Pmc4209234
Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW, Godwin AK. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol. 2009 Apr;113(1):21-7.   PMCID: PMC 2741166
Burtness BA, Manola J, Axelrod R, Argiris A, Forastiere AA. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Ann Oncol. 2008 May;19(5):977-83.
Ozols RF, Bookman MA, du Bois A, Pfisterer J, Reuss A, Young RC. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. Gynecol Oncol. 2006 Oct;103(1):1-6.
Dell DD. Deep vein thrombosis in the patient with cancer. Clinical journal of oncology nursing. 2002 Jan;6(1):43-6.
Hudes G, Haas N, Yeslow G, Gillon T, Gunnarsson PO, Ellman M, Nordle O, Eriksson B, Miller L, Cisar L, Kopreski M, Viaro D, Hartley-Asp B. Phase I clinical and pharmacologic trial of intravenous estramustine phosphate. J Clin Oncol. 2002 Feb 15;20(4):1115-27.
Haas N, Roth B, Garay C, Yeslow G, Entmacher M, Weinstein A, Rogatko A, Babb J, Minnitti C, Flinker D, Gillon T, Hudes G. Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer. Urology. 2001 Jul;58(1):59-64.
Murphy BA, Leong T, Burkey B, Langer C, Forastiere A. Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous carcinoma of the head and neck: an Eastern Cooperative Oncology Group Trial (E3393). Am J Clin Oncol. 2001 Feb;24(1):64-6.
O'Dwyer PJ, Manola J, Valone FH, Ryan LM, Hines JD, Wadler S, Haller DG, Arbuck SG, Weiner LM, Mayer RJ, Benson AB. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. J Clin Oncol. 2001 May;19(9):2413-21.
Bookman MA, Blessing JA, Hanjani P, Herzog TJ, Andersen WA. Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2000 Jun;77(3):446-9.
Pendyala L, Creaven PJ, Schwartz G, Meropol NJ, Bolanowska-Higdon W, Zdanowicz J, Murphy M, Perez R. Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione. Clin Cancer Res. 2000 Apr;6(4):1314-21.
O'Dwyer PJ, Laub PB, DeMaria D, Qian M, Reilly D, Giantonio B, Johnston AL, Wu EY, Bauman L, Clendeninn NJ, Gallo JM. Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion. Clin Cancer Res. 1996 Oct;2(10):1685-92.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Intravenous Infusions

drug therapy Intravenous Infusions Aged adverse effects Female administration & dosage therapeutic use Drug Administration Schedule Drug Dose-Response Relationship pathology Male Adult Middle Aged Human Disease-Free Survival chemically induced Middle Age Treatment Outcome Antineoplastic Agents Antineoplastic Combined Chemotherapy Protocols pharmacokinetics Paclitaxel US Gov't Support-PHS Prognosis Neoplasm Staging 80 and over Aged Monoclonal Antibodies-Humanized Ovarian Neoplasms Nausea Neoplasms Maximum Tolerated Dose effects Survival Analysis mortality adverse secondary metabolism Patient Safety Fatigue drug effects therapeutic Neoplasm Invasiveness Neoplasm Drug Resistance Cisplatin Kaplan-Meier Estimate Carboplatin analogs & derivatives use Squamous Cell Carcinoma blood statistics & numerical data Oral Administration diagnosis Topotecan dosage Vomiting Non-US Gov't Support Metabolic Clearance Rate Hypotension Prospective Studies etiology Risk Assessment Prostatic Neoplasms Head and Neck Neoplasms Combined Modality Therapy Epothilones therapy Area Under Curve United States Parenteral Infusions Local Neoplasm Recurrence Estramustine Protective Agents Taxoids Pain Peripheral Nervous System Diseases Sarcoma Interferon Alfa-2a Follow-Up Studies Randomized Controlled Trials as Topic Thrombocytopenia Proteomics Liver Edema antibodies Heparin Myeloid Leukemia-Acute Mesna Rheumatoid Arthritis methods Adenocarcinoma Bevacizumab Phase III Clinical Trials as Topic Flushing Antineoplastic Antibiotics Survival Fluorouracil Bilirubin Internationality Rituximab Phosphonoacetic Acid Sulfhydryl Compounds Homocysteine immunology hospital costs Cytoreduction Surgical Procedures Alkylating Antineoplastic Agents administration & Case Report Acetaldehyde Adjuvant Chemotherapy economics Hematologic Diseases urine Cysteine humanized Alanine Transaminase Integrin alpha5beta1 Aspartic Acid pharmacology Academic Medical Centers Anaphylaxis Single-Blind Method Biological Tumor Markers Glandular and Epithelial Neoplasms rituximab Liver Diseases Peritoneal Neoplasms Aspartate Aminotransferases Recurrence Confidence Intervals Survival Rate antagonists & inhibitors Azacitidine arthritis Home Infusion Therapy Gonadorelin Cyclophosphamide Early stage ovarian cancer Thrombophlebitis Enzyme Inhibitors prevention & control Indoles Cystic Neoplasms-Mucinous-and Serous Time Factors Abatacept Severity of Illness Index abatacept Cervix Neoplasms Neoplasm Metastasis
Last updated on Wednesday, February 05, 2020